Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Sponsor: ACADIA Pharmaceuticals Inc.
This PHASE3 trial investigates Adjunctive Treatment of Major Depressive Disorder and is currently completed. ACADIA Pharmaceuticals Inc. leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Jan 2021 — Present [monthly]
Completed PHASE3
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Mar 2020 — Jul 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Mar 2020 [monthly]
Recruiting PHASE3
-
Dec 2019 — Jan 2020 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Oct 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ACADIA Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgrade, Serbia , Bełchatów, Poland , Blackpool, United Kingdom , Bydgoszcz, Poland , Cape Town, South Africa , Dnipro, Ukraine , Durbanville, South Africa , Gdańsk, Poland , Helsinki, Finland , Kharkiv, Ukraine and 27 more locations